Synaptophysin-like 2 expression correlates with lymph node metastasis and poor prognosis in colorectal cancer patients

Figure 1 Synaptophysin-like 2 expression levels and survival analyses in colorectal cancer. A: Synaptophysin-like 2 (SYPL2) expression in 275 colon cancer tissue and 349 normal colon tissue samples and in 92 rectal cancer tissue and 318 normal rectal tissue samples from Gene Expression Profiling Interactive Analysis (GEPIA) (P < 0.05); B: SYPL2 expression in 203 colorectal cancer (CRC) tissue and 160 normal colorectal tissue samples from GSE87211 (P < 0.01); C: SYPL2 expression in 98 CRC samples, 98 adjacent normal samples, and 50 healthy colon tissue samples from GSE44076 (P < 0.001); D: SYPL2 expression in tumor tissues and adjacent normal colon tissue samples from 20 CRC patients who underwent tumor resection at Fuyang People’s Hospital (P < 0.05). The average expression of SYPL2 in the 20 normal tissue samples was regarded as a reference; E: Associations of SYPL2 expression with the overall survival (OS) of CRC patients from GEPIA (P < 0.05); F: Associations of SYPL2 expression with the disease-free survival (DFS) of CRC patients from GEPIA (P < 0.05); G: Associations of SYPL2 expression with the OS of CRC patients from the Kaplan-Meier plotter (P < 0.05); H: Associations of SYPL2 expression with the DFS of CRC patients from the Kaplan-Meier plotter (P < 0.05); I: Associations of SYPL2 expression with the OS of stage II CRC patients from TCGA (P < 0.05); J: Associations of SYPL2 expression with the OS of stage III CRC patients from TCGA (P < 0.05). ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. SYPL2: Synaptophysin-like 2; HR: Hazards ratio.

Figure 2 Correlations of tumor expression of synaptophysin-like 2 among the 20 colorectal cancer patients who underwent tumor resection at Fuyang People’s Hospital. A: T stage; B: Lymph node metastasis. SYPL2: Synaptophysin-like 2; LNM: Lymph node metastasis. ^bP < 0.01.

Figure 3 Correlations of levels of synaptophysin-like 2 expression with Kirsten rat sarcoma BRAF^V600E, and P53 mutations from GSE103479 and levels of expression of the key target genes KDR, epidermal growth factor receptor, vascular endothelial growth factor A, CD274, PDCD1, and CTLA4 from Gene Expression Profiling Interactive Analysis. A: Association of synaptophysin-like 2 (SYPL2) expression with KRAS, BRAF^V600E, P53 mutation; B: Association of SYPL2 expression with KDR, epidermal growth factor receptor, vascular endothelial growth factor A, CD274, PDCD1, cytotoxic T-lymphocyte-associated protein 4. SYPL2: Synaptophysin-like 2; MT: Mutation type; WT: Wild type; EGFR: Epidermal growth factor receptor; VEGFA: Vascular endothelial growth factor A; CTLA4: Cytotoxic T-lymphocyte-associated protein 4.

Figure 4 Levels of synaptophysin-like 2 expression in colorectal cancer patients from GSE60331 who did and did not respond to bevacizumab treatment. ^aP < 0.05.

Figure 5 Effects of synaptophysin-like 2 expression level on the immune microenvironment in colorectal cancer from the Cancer Genome Atlas. A: Statistical chart after using the CIBERSORT method, showing the different proportions of immune cells in groups of patients with high (red) and low (blue) synaptophysin-like 2 expression; B-E: Survival analyses of patient subgroups. SYPL2: Synaptophysin-like 2; HR: Hazards ratio.

Figure 6 Enrichment plots from the Gene set enrichment analysis. A: Gene Ontology; B: Kyoto Encyclopedia of Genes and Genomes.